This statistic shows the number of registrations of newly diagnosed cases of ovarian cancer in England in 2022, by age group. The most affected age group was among 75 to 79 year olds, with 908 cases reported in 2022.

This statistic shows the 10-year probability of a women developing ovarian cancer in the United States as of 2018. According to the data, a women at the age of ** has a *** percent probability of developing ovarian cancer within the next 10 years. However, a women at the age of ** has a *** percent probability of developing ovarian cancer within the next 10 years.

IntroductionOvarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies.MethodsWe examined ovarian cancer incidence, mortality, and disability-adjusted life years (DALYs) using age-standardized rates from the Global Burden of Disease, Injuries, and Risk Factors Study 2021. high body mass index and occupational asbestos exposure were linked with death and DALYs. Data are presented as averages with 95% uncertainty intervals (UIs).ResultsIndonesia had 13 250 (8 574–21 565) ovarian cancer cases in 2021, with 5 296 (3 520–8958) deaths and 186 917 (121 866–309 820) DALYs. The burden increased by 233.53% for new cases, 221.95% for mortalities, and 206.65% for DALYs. The age-standardized rate also increased from 1990 to 2021. Ovarian cancer burden increased with age but declined in the 50+ year age group. According to the sociodemographic index, the gross domestic product per capita and number of obstetricians and oncologic gynecologists in provinces showed different trends.ConclusionsIndonesian ovarian cancer rates are rising despite gynecologic oncologists in 24 of 34 provinces. These findings will help policymakers and healthcare providers identify ovarian cancer prevention and control gaps.

Ovarian Cancer Diagnostics and Therapeutics Market Outlook

The global ovarian cancer diagnostics and therapeutics market size was valued at approximately USD 2.6 billion in 2023 and is projected to reach USD 5.5 billion by 2032, registering a compound annual growth rate (CAGR) of 8.5% during the forecast period. The growth in this market is primarily driven by advancements in medical technology, increased awareness about cancer diagnosis and treatment options, and the rising prevalence of ovarian cancer worldwide. With improved diagnostic methodologies and an expanding portfolio of therapeutic options, the market is poised for significant progress over the next decade.

One of the primary growth factors for the ovarian cancer diagnostics and therapeutics market is the increasing global incidence of ovarian cancer. Ovarian cancer is one of the leading causes of cancer deaths among women, and its growing prevalence is a critical factor necessitating the development and implementation of advanced diagnostic and therapeutic solutions. The aging population, especially in developed regions, is also contributing to the rising incidence rates, as ovarian cancer risk significantly increases with age. Moreover, lifestyle changes and genetic predispositions are further exacerbating the potential for increased cases, thereby fueling market demand for effective diagnostic tools and therapeutic options.

Another significant growth factor is the technological advancements in the field of cancer diagnostics and treatment. Breakthroughs in imaging technologies, molecular diagnostics, and personalized medicine have revolutionized how ovarian cancer is detected and treated. Innovations such as next-generation sequencing and liquid biopsies are transforming the diagnostic landscape by enabling early detection and personalized treatment regimens. Additionally, the development and approval of new drugs and treatment modalities, including targeted therapy and immunotherapy, are enhancing treatment efficacy and patient outcomes, thus propelling market growth.

Government initiatives and funding for cancer research and treatment also play a crucial role in the growth of the ovarian cancer diagnostics and therapeutics market. Increased government spending on healthcare infrastructure, coupled with supportive policies to facilitate cancer research, is encouraging the development of new diagnostic and therapeutic solutions. Public awareness campaigns and educational programs about the importance of early detection and treatment of ovarian cancer are also contributing to the growth of the market by increasing patient awareness and encouraging proactive healthcare measures.

Regionally, North America holds a dominant position in the ovarian cancer diagnostics and therapeutics market, owing to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, improving healthcare infrastructure, and a rising patient pool due to the increasing prevalence of ovarian cancer. The rapid economic growth in countries like China and India, coupled with growing awareness and availability of advanced healthcare solutions, are bolstering the market prospects in this region.

Product Type Analysis

The ovarian cancer diagnostics and therapeutics market is segmented into two primary product types: diagnostics and therapeutics. The diagnostics segment includes various methods used for early detection and confirmation of ovarian cancer, such as imaging tests, blood tests, and biopsies. Imaging tests, including ultrasound and CT scans, are essential tools in diagnosing ovarian cancer as they provide detailed images of the ovaries and surrounding areas, helping detect any abnormal growths. Blood tests, particularly those measuring cancer antigens like CA-125, are widely utilized as they offer non-invasive and cost-effective means of preliminary cancer detection. Additionally, biopsy procedures, though invasive, provide definitive diagnosis by allowing pathological examination of ovarian tissue.

The therapeutics segment encompasses several treatment modalities used to manage and treat ovarian cancer, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Chemotherapy remains the cornerstone of ovarian cancer treatment, often administered post-surgery to eradicate any residual cancer cells. Despite its effectiveness, chemotherapy is associated with significant side effects, prompting

The Synthetic Ovarian Cancer Prediction Dataset is created for educational and research purposes, particularly for the exploration and development of machine learning models to predict ovarian cancer presence and progression. The dataset includes anonymized, synthetic clinical and laboratory data for 100,000 subjects, simulating real-world patterns of ovarian cancer indicators.

Dataset Features

The dataset includes 51 features representing a wide range of blood biomarkers, demographics, and diagnostic markers commonly associated with ovarian cancer. These include:

• SUBJECT_ID: Unique identifier for each patient.
• Age: Age of the patient (in years).
• Menopause: Menopausal status (encoded as integers).
• AFP, CA125, CA19-9, CA72-4, HE4, CEA: Tumor markers relevant to cancer diagnostics.
• Various Blood Markers: Including ALB, AST, ALT, ALP, BUN, CREA, TP, TBIL, DBIL, IBIL, GGT, GLU, and others.
• Electrolytes and Ions: Such as Na, K, Ca, Mg, CL, PHOS, CO2CP.
• Hematological Measures: Including HGB, HCT, RBC, WBC subtypes (NEU, LYM, MONO, EO, BASO), PLT, RDW, MCH, MCV, MPV, PDW, and PCT.
• TYPE: Target variable indicating cancer classification (encoded as integers).

Distribution

https://storage.googleapis.com/opendatabay_public/27816028-a67a-429c-84f6-ce88d59ae85f/65e968756c92_ovarian_cancer_visuals.png" alt="Synthetic dataset ovarian_cancer_visuals.png">

Usage

This dataset can be used for the following applications:

• Cancer Research: Explore associations between biomarkers and ovarian cancer diagnosis or prognosis.
• Predictive Modeling: Develop machine learning or statistical models to classify or predict ovarian cancer types based on lab results and demographic data.
• Clinical Research: Study the diagnostic value of various tumor markers in ovarian cancer.
• Educational Purposes: Serve as a resource for training students and professionals in data science, bioinformatics, and healthcare analytics.

Coverage

The dataset is fully synthetic and anonymized, adhering to privacy standards and suitable for open-access educational and research purposes. It captures realistic data distributions for key clinical metrics involved in ovarian cancer detection and monitoring.

License

CC0 (Public Domain)

Who Can Use It

• Medical Researchers and Oncologists: To identify biomarker trends and diagnostic criteria for ovarian cancer.
• Data Scientists and Machine Learning Engineers: To build and evaluate predictive models on medical data.
• Healthcare Educators and Students: For academic instruction, project work, and data analysis practice in clinical research settings.

This statistic displays the incidence and fatal rate of ovarian cancer in Hong Kong from 2017 to 2020. According to the hospital authority of Hong Kong, the age-standardized death rate of ovarian cancer in Hong Kong was around 3.1 per 100,000 female population in 2020.

Ovarian Cancer Market Outlook

The global ovarian cancer market size was estimated to be USD 3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This robust growth is driven by several factors, including advancements in medical technology, increasing awareness about early diagnosis, and the rising prevalence of ovarian cancer worldwide. By 2032, the market is expected to reach approximately USD 6.5 billion, underscoring the critical need for innovative treatment strategies and accessible healthcare solutions across various regions. Such growth is largely attributed to increasing investments in research and development, leading to novel therapeutic options and the expansion of healthcare infrastructure globally.

One of the significant growth factors for the ovarian cancer market is the increasing incidence and prevalence of the disease. Ovarian cancer remains one of the leading causes of cancer-related deaths among women, primarily due to late diagnosis. Early-stage ovarian cancer often presents with nonspecific symptoms, resulting in late-stage detection when treatment options are limited. This challenge has prompted greater focus on developing better diagnostic tools and screening methods, which is expected to drive market growth. Additionally, lifestyle factors, genetic predispositions, and increasing age are contributing to the rising incidence rates, further scaling the demand for effective treatment solutions.

The advent of precision medicine is another pivotal factor propelling the growth of the ovarian cancer market. Precision medicine involves tailoring healthcare treatments to individual patients based on genetic, environmental, and lifestyle factors. This approach is gaining traction as it promises to improve treatment efficacy and patient outcomes. The development of targeted therapies, which aim to attack specific cancer cells while sparing healthy ones, represents a significant advancement. These therapies are becoming increasingly integrated into standard treatment protocols, supported by favorable clinical outcomes and regulatory approvals. As a result, the market is witnessing an influx of targeted therapy options, offering renewed hope for patients and driving market expansion.

Increasing awareness and advocacy efforts are also playing a crucial role in the growth of the ovarian cancer market. Various organizations and stakeholders are actively involved in raising awareness about ovarian cancer symptoms, risk factors, and the importance of regular medical check-ups. Such initiatives have led to greater patient education and improved healthcare-seeking behaviors, contributing to earlier diagnoses and better management of the disease. Additionally, governmental and non-governmental funding for ovarian cancer research is bolstering the market by facilitating the development of new drugs and treatment methodologies. These collaborative efforts are poised to sustain the market's growth trajectory in the coming years.

The development and availability of Gynaecological Cancer Drugs are pivotal in addressing the treatment needs of ovarian cancer patients. These drugs are specifically designed to target the unique biological characteristics of gynecological cancers, including ovarian cancer, providing more effective and tailored treatment options. The innovation in this field is driven by extensive research and development efforts, focusing on improving drug efficacy and minimizing side effects. As a result, patients have access to a broader range of therapeutic options, enhancing their chances of successful treatment outcomes. The integration of these drugs into standard treatment protocols is supported by clinical evidence demonstrating their benefits in managing ovarian cancer. As the market for gynaecological cancer drugs continues to expand, it is expected to play a significant role in the overall growth of the ovarian cancer treatment landscape.

Regionally, North America dominates the ovarian cancer market, owing to its well-established healthcare infrastructure, high prevalence of the disease, and extensive research activities. The presence of leading pharmaceutical companies and research institutions further supports market growth in this region. Europe follows closely, with countries like Germany, France, and the UK making substantial investments in cancer research and treatment. The Asia Pacific region is expected to witness the fastest growth rate, driven by increasing healthcare awareness and improving healthcare infrastructure. Rapid urbanization and e

In 2023, the incidence rate for ovary cancer in Canada was expected to be 13.2 per 100,000 population among females. This statistic displays the age-standardized rate of ovary cancer cases among females in Canada between 1988 and 2020, with forecasts from 2021 to 2023.

ObjectivesIt is important to assess the burden of ovarian cancer related premature death so as to develop appropriate evidence-based care and improve women’s health. This study aimed to characterize the long-term trends in mortality, survival and disease burden of ovarian cancer in Shanghai, China.Materials and MethodsCo-morbidities, crude mortality rate (CMR), age-standardised mortality rate by Segi’s world standard population (ASMRW), years of life lost (YLL), and survival rates were analysed. Temporal trends for the mortality rates and disease burden were analyzed using the Joinpoint Regression Program. Mortality rate increases by demographic and non-demographic factors were estimated by the decomposition method.ResultsA total of 1088 ovarian cancer as underlying cause of deaths were recorded. CMR and ASMRW were 4.82/105 and 2.32/105 person-years, respectively. The YLL was 16372.96 years, and the YLL rate was 72.46/105 person-years. The YLL rate increased only in the age group of 70-79 years (P = 0.017). The survival rates of ovarian cancer patients did not improve during the ten year period (2005-2015). The top co-morbidities were diseases of the respiratory system, digestive system, and circulatory system. The rates of ovarian cancer deaths caused by non-demographic and demographic factors increased by 21.29% (95%CI: 4.01% to 41.44%, P = 0.018) and 25.23% (95%CI: 14.64% to 36.81%, P < 0.001), respectively.ConclusionsPopulation ageing and all cause of death may affect ovarian cancer related deaths in Pudong, Shanghai. The high mortality and the stagnant survival rates suggest the need for more efforts in targeted prevention and treatment of this disease.

This statistic displays the most dangerous age for getting ovarian cancer according to women in Hong Kong as of 2017. According to a telephone interview conducted between December 2016 and January 2017, almost 40 percent of the respondents thought that women between 45 and 54 years old were most likely to get ovarian cancer.

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata Note: Definition includes Uterine, Ovarian, and Cervical Cancers. *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Background: Population-based data on borderline ovarian tumors (BOTs) are scarce and information regarding recent trends in incidence, treatment and survival is lacking. The purpose of this study was to analyze these trends in the Netherlands and to assess the risk of developing a subsequent invasive ovarian tumor. Material and methods: All consecutive patients diagnosed with BOTs between 1993 and 2016 (n = 7113) were identified from the Netherlands Cancer Registry (NCR). Annual age-adjusted incidence rates were calculated. Relative survival (RS) analyses and multivariable analyses estimating excess mortality were conducted. Patients with a subsequent invasive ovarian tumor were identified by the NCR. Results: Age-adjusted incidence increased from 2.1/100,000 person-years in 1993 to 4.2/100,000 in 2011, after 2011 the incidence declined. The proportion of bilateral tumors decreased over time from 16% in 1993–1998 to 11% in 2005–2010 and remained stable onwards. Survival improved over time (excess mortality ratioadjusted 2011–2016 versus 1993–1998: 0.25; 95%CI: 0.13–0.47). Five-year RS increased from 91% in 1993–1998 to 98% in 2011–2016 and 10-year RS from 88% in 1993–1998 to 96% in 2005–2010. Fewer patients were treated with chemotherapy (4.4% in 1993–1998 versus 0.7% in 2011–2016). During a median follow-up time of 8 years, 0.9% developed a subsequent invasive ovarian carcinoma. Conclusions: The incidence of BOTs increased over time from 1993 until 2010 but declined since 2011. This decline may be partly due to changes in the classification of gynecological tumors, as serous BOTs are now more often diagnosed as low grade serous ovarian cancers. Survival is high and has improved since 1993. The risk of a subsequent invasive ovarian carcinoma seems low.

• Wang et al. Weakly Supervised Deep Learning for Prediction of Treatment Effectiveness on Ovarian Cancer from Histopathology Images. Computerized Medical Imaging and Graphics. https://doi.org/10.1016/j.compmedimag.2022.102093
• Wang, CW., Chang, CC., Khalil, M.A. et al. Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer. Sci Data 9, 25 (2022). https://doi.org/10.1038/s41597-022-01127-6

Participants in this cohort are women identified from medical records and family records from the Department of Oncology , Lund. The inclusion criteria is that the woman should belong to families with a high risk of developing breast cancer as well as being known carriers of mutations in BRCA1 or BRCA2, or be related in the first or second generation to an individual with breast cancer or individual without breast cancer who are carriers of mutations in the genes BRCA1 or BRCA2. Study participants must be under 40 years old and still be menstruating.

“A family at high-risk for breast cancer” is considered if three women had been diagnosed with breast cancer and at least one of these was below age 50 years at diagnosis, or if two women had been diagnosed with breast cancer and at least one was below age 40 years at diagnosis, or if one woman diagnosed with breast cancer prior to age 30 years.

The collection, which is still ongoing, started in 1996 and consisted of 300 cases in 2010.

The selected women were contacted with a letter with information about the study and thereafter called and asked if they wanted to participate. A letter containing a comprehensive questionnaire was sent out to the women who had chosen to participate. The questions concerned areas such as fertility , breastfeeding, contraceptives, other medications, smoking and dietary issues. Participants were also called in for sampling and body measuremens (such as weight, length and different breast dimensions). Blood samples were taken on two occasions during the menstrual cycle : day 5-10 and ~ 18-23 days.

Purpose:

To study risk factors in young women of high risk for breast and ovarian cancer.

Data collection is ongoing. In 2010, the study consisted of 300 cases.

As of 2024, over *********** women were living with a diagnosis of breast, uterus (body), ovarian, or cervix cancer in Italy. Among them, the majority had a diagnosis of breast cancer, with ******* cases. The graph presented shows the number of people living with a diagnosis of breast, uterus (body), ovarian, or cervix cancer among women in Italy as of 2024.

Aim: We aimed to estimate the disease burden and risk factors attributable to ovarian cancer, and epidemiological trends at global, regional, and national levels.Methods: We described ovarian cancer data on incidence, mortality, and disability-adjusted life-years as well as age-standardized rates from 1990 to 2017 from the Global Health Data Exchange database. We also estimated the risk factors attributable to ovarian cancer deaths and disability-adjusted life-years. Measures were stratified by region, country, age, and socio-demographic index. The estimated annual percentage changes and age-standardized rates were calculated to evaluate temporal trends.Results: Globally, ovarian cancer incident, death cases, and disability-adjusted life-years increased by 88.01, 84.20, and 78.00%, respectively. However, all the corresponding age-standardized rates showed downward trends with an estimated annual percentage change of −0.10 (−0.03 to 0.16), −0.33 (−0.38 to −0.27), and −0.38 (−0.32 to 0.25), respectively. South and East Asia and Western Europe carried the heaviest disease burden. The highest incidence, deaths, and disability-adjusted life-years were mainly in people aged 50–69 years from 1990 to 2017. High fasting plasma glucose level was the greatest contributor in age-standardized disability-adjusted life-years rate globally as well as in all socio-demographic index quintiles and most Global Disease Burden regions. Other important factors were high body mass index and occupational exposure to asbestos.Conclusion: Our study provides valuable information on patterns and trends of disease burden and risk factors attributable to ovarian cancer across age, socio-demographic index, region, and country, which may help improve the rational allocation of health resources as well as inform health policies.

Ovarian Cancer Molecular Diagnostics Market Outlook

The global ovarian cancer molecular diagnostics market size is anticipated to witness a significant growth trajectory, expanding from approximately USD 1.5 billion in 2023 to an estimated USD 3.2 billion by 2032, registering a robust CAGR of 8.6% during the forecast period. This impressive growth can be attributed to the increasing prevalence of ovarian cancer, advancements in molecular diagnostic technologies, and the rising demand for early detection methods. With ovarian cancer being one of the leading causes of cancer-related deaths among women, the need for effective diagnostic solutions continues to be a critical growth driver in this market.

The growing awareness about the benefits of early diagnosis is a major factor propelling the growth of the ovarian cancer molecular diagnostics market. Early detection significantly increases the chances of successful treatment, and with technological advancements in molecular diagnostics, healthcare providers can now offer more accurate and timely diagnoses. The integration of advanced molecular technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR) has revolutionized diagnostic practices, enabling the identification of specific genetic mutations associated with ovarian cancer. This not only facilitates early intervention but also aids in tailoring personalized treatment plans, thereby improving patient outcomes. Additionally, government initiatives and funding aimed at cancer research and early diagnosis further contribute to market growth.

Another key growth factor is the rise in healthcare expenditure and improving healthcare infrastructure globally, particularly in emerging economies. As healthcare systems strengthen, there is a corresponding increase in the availability and accessibility of advanced diagnostic tools. This is coupled with a growing emphasis on precision medicine, which relies heavily on molecular diagnostics to provide insights into individual patient profiles and targeted therapies. The demand for molecular diagnostic solutions is further bolstered by the aging population, as the risk of developing ovarian cancer increases with age. Consequently, markets in regions such as Asia Pacific are witnessing substantial growth, driven by increased investment in healthcare and rising awareness among both healthcare professionals and patients.

Furthermore, the continuous advancements in technology and the development of novel diagnostic methods are leading to more effective and less invasive diagnostic approaches, which are crucial for patient compliance and satisfaction. Innovations such as liquid biopsies, which allow for the detection of cancer markers in blood, are gaining traction as they offer a non-invasive alternative to traditional tissue biopsies. These advancements not only enhance the diagnostic accuracy but also reduce the discomfort and risks associated with invasive procedures. Moreover, the ongoing research and development activities are expected to yield new biomarkers and diagnostic platforms, providing lucrative opportunities for market participants.

Regionally, North America currently dominates the ovarian cancer molecular diagnostics market, attributed to its well-established healthcare infrastructure, high adoption rates of advanced diagnostics, and significant investment in cancer research. Europe follows closely, supported by favorable governmental policies and the presence of a large patient pool. The Asia Pacific region is projected to exhibit the highest growth rate during the forecast period, fueled by increasing healthcare expenditure, improving medical facilities, and growing awareness regarding early cancer detection. Latin America and the Middle East & Africa also show potential for market expansion, though at a relatively slower pace due to economic constraints and limited access to advanced healthcare technologies.

Product Type Analysis

The ovarian cancer molecular diagnostics market can be segmented by product type, which includes instruments, reagents, and software. Instruments are a crucial component of the diagnostic process as they provide the necessary tools for conducting various molecular diagnostic tests. These instruments often require significant initial investment; however, they are integral to labs and healthcare facilities focused on cancer diagnostics. The demand for advanced instruments is primarily driven by the growing trend towards automation in laboratories, which improves efficiency and accuracy in testing. Companies in this segment are focusing on innovation, developing instruments that are more user-friend

In our study, we have generated proteomic and genomic (RNA sequencing and whole genome sequencing) profiles from high grade serous ovarian cancer (HGSOC) tumor biopsies. All biospecimens are formalin-fixed, parrafin-embedded (FFPE) tissues and annotated for patient sensitivity to platinum chemotherapy (refractory or sensitive). For all 174 tumors that were analyzed, we have H&E-stained and imaged the first and last sections (“bookend”) cut from each FFPE block to allow study of tumor pathology. These H&E pathology images are uploaded in this dataset. The 174 tumors represented 158 unique patients (imaging was performed on two FFPE blocks for a small subset of patients where additional tumor mass was required for proteomic analysis). The bookend FFPE slides were cut at 4 μm thickness using a microtome and mounted on glass slides (Leica Biosystems Cat# 3800040) for H&E staining. Digital images of the H&E slides were recorded using a ScanScope AT Slide Scanner (Leica Aperio Technologies, Vista, CA, USA) under 20X objective magnification (0.5 μm resolution). Images were analyzed by HALO Image Analysis Platform software (Indicta Labs, Albuquerque, New Mexico, USA).

The following clinical data are also provided for these subjects:

• Image file name (combination of Image Name and Image ID) and corresponding sample IDs
• Chemotherapy response status: (sensitive/refractory; refractory is defined in our study as clinical ovarian cancer that progresses while on platinum-based therapy or within 4 weeks)
• neo-adjuvant treatment (yes/no)
• Tumor location
• Tumor grade, stage, substage
• Patient age
• Patient ethnicity
• Patient race
• Age of sample

The goals of the study were to understand mechanisms of platinum resistance in epithelial ovarian cancers (EOCs) in order to: i) predict EOCs that will respond to DNA-damaging platinum therapy, and ii) identify potential new drug targets in resistant disease to point to desperately needed new therapeutic approaches. The ability to predict platinum-resistant/refractory disease would be clinically impactful by enabling the immediate triage of patients with refractory disease to clinical trials of experimental therapies, avoiding use of ineffective standard of care chemotherapy and helping to identify novel treatments. In this study, we generated proteomic and genomic (RNA sequencing and whole genome sequencing) profiling datasets and H&E images from high grade serous ovarian cancer (HGSOC) tumor biopsies representing platinum-sensitive and platinum-refractory disease.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

This dataset contains the probability of cancer at different CA125 levels derived from logistic regression analysis and supporting the PLOS Medicine publication: "The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study". The dataset is in Excel format. Sheet A provides the probability of ovarian cancer (with associated 95% confidence intervals) for CA125 levels between 1-1000 U/ml. Sheet B provides the probability of invasive ovarian cancer (with associated 95% confidence intervals) for CA125 levels between 1-1000 U/ml. Sheet C provides the probability of all cancer (with associated 95% confidence intervals) for CA125 levels between 1-1000 U/ml. Sheet D provides the probability of ovarian cancer (with associated 95% confidence intervals) for CA125 levels between 1-1000 U/ml for women aged 30, 40, 50, 60, 70 and 80 years of age.